Free Trial
→ Trump, Schiff and Dalio all point to the same warning sign (From USA Capital Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$148.05
+0.6%		$146.34
$90.90
▼
$156.92
$364.80B0.1310.55 million shs1.70 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.49%-1.94%+1.23%+8.63%+62.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$148.05
+0.6%		$146.34
$90.90
▼
$156.92
$364.80B0.1310.55 million shs1.70 million shs
The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.49%-1.94%+1.23%+8.63%+62.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.59
Moderate Buy$155.745.75% Upside

Current Analyst Ratings Breakdown

Latest MRK, BVXP, AGY, and VLG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Argus logo
Argus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageStrong-Buy
11/3/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DZ Bank AG logo
DZ Bank
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Hold$153.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Freedom Broker
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetHold$125.00 ➝ $140.00
11/2/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$145.00 ➝ $155.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$165.00 ➝ $175.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetSector Perform$145.00 ➝ $140.00
10/30/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$170.00 ➝ $171.00
10/26/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetOverweight$150.00 ➝ $180.00
10/19/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/12/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$125.00 ➝ $145.00
(Data available from 11/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B5.58$11.36 per share12.96$18.23 per share8.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$0.97151.8316.226.793.64%16.73%5.88%N/A

Latest MRK, BVXP, AGY, and VLG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.09$2.49+$0.40$2.04$17.33 billion$18.09 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.31%+5.75%350.52%14 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.11
1.35
1.14

Institutional Ownership

CompanyInstitutional Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.46 billionOptionable

Recent News About These Companies

Merck shares hit over 1-year high as Q3 beats estimates and outlook is raised
 |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/merck-kgaa-q3-profit-slumps-065915742.html
Merck to Participate in the Jefferies Global Healthcare Conference in London
 |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-participate-jefferies-global-healthcare-114500983.html
Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year
November 11 at 6:28 PM  |  247wallst.comhttps://247wallst.com/investing/2026/11/11/americans-fill-prescriptions-every-month-and-90000-across-these-3-drugmakers-pays-3650-a-year/
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
November 11 at 9:56 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/long-ideas/26/11/63141495/democrats-drug-pricing-stocks-exclusive?utm_source=snapi
Up 42% since January: Why Merck is defeating the patent cliff
November 11 at 8:25 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/42-since-january-why-merck-091635980.html
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom (MRK)
...
November 11 at 8:10 AM  |  marketbeat.comhttps://www.marketbeat.com/articles/the-ai-debt-bill-is-coming-due-but-biotech-has-revenue-to-show-for-the-boom/
Merck & Co., Inc. $MRK Stock Sold by M&G PLC
November 11 at 5:23 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-sold-by-mg-plc-2026-11-11/
Merck Shares Rose Even As Profit Fell
November 11 at 3:23 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-shares-rose-even-profit-043542431.html
Merck (MRK) Could Be 7% Undervalued As MASH Trial Data Lifts Optimism
November 11 at 3:23 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-mrk-could-7-undervalued-051334927.html
Merck vs. Gilead Sciences: Which Dividend Stock Pays You More in 10 Years?
November 10 at 5:23 PM  |  tikr.comT
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor
November 10 at 1:14 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261029670739/en/fda-approves-pimjetmi%c2%ae-pimicotinib-for-patients-with-tenosynovial-giant-cell-tumor/
Merck & Co., Inc. $MRK Stock Bought by Red Cedar Investment Management LLC
November 10 at 6:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-bought-by-red-cedar-investment-management-llc-2026-11-10/
27,441 Merck & Co., Inc. $MRK Shares Purchased by Vestor Capital LLC
November 10 at 5:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-27441-merck-co-inc-mrk-shares-purchased-by-vestor-capital-llc-2026-11-10/
884,504 Merck & Co., Inc. $MRK Shares Sold by Beutel Goodman & Co Ltd.
November 10 at 4:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-884504-merck-co-inc-mrk-shares-sold-by-beutel-goodman-co-ltd-2026-11-10/
Merck & Co., Inc. $MRK Stock Purchased by Fulcrum Asset Management LLP
November 10 at 4:04 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-merck-co-inc-mrk-stock-purchased-by-fulcrum-asset-management-llp-2026-11-10/
37,653 Merck & Co., Inc. $MRK Shares Sold by AEGON ASSET MANAGEMENT UK Plc
November 10 at 3:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-37653-merck-co-inc-mrk-shares-sold-by-aegon-asset-management-uk-plc-2026-11-10/
INVA or MRK: Which Is the Better Value Stock Right Now?
November 9 at 4:08 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/inva-mrk-better-value-stock-154003956.html
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
November 9 at 4:08 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-announces-positive-results-phase-180500903.html
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis
November 9 at 1:05 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20261109820711/en/merck-announces-positive-results-from-phase-2b-trial-of-efinopegdutide-in-adults-with-metabolic-dysfunction-associated-steatohepatitis-mash-and-stage-2-3-fibrosis/
INVA or MRK: Which Is the Better Value Stock Right Now?
November 9 at 12:41 PM  |  zacks.comhttps://www.zacks.com/stock/news/3026595/inva-or-mrk-which-is-the-better-value-stock-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-3026595
Merck (MRK) Starts ENHANCE 3 COPD Trial As Cancer Drug Review Nears
November 9 at 11:08 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/merck-mrk-starts-enhance-3-110704680.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
White Tesla sports car parked at a launch site with rocket boosters visible against a sunset sky.
Tesla's Roadster Reveal Hints at 2 Much Bigger Moves
By Sam Quirke | October 19, 2026
Salesforce cloud logo in a futuristic tech setting, highlighting CRM enterprise software and AI platform growth.
Salesforce Fuels AI Engine With $5.66B Braze Buyout
By Jeffrey Neal Johnson | October 21, 2026
Industrial energy facility with cooling units, piping systems, and a large turbine beside flowing water.
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
By Chris Markoch | October 18, 2026
Lemonade logo over a house graphic with icons for home, renters, car, and pet insurance, a dog and cat in the yard.
Lemonade's Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
By Thomas Hughes | November 8, 2026
Vaccine vial and syringe on a lab surface with DNA strands and virus particle illustrations in the background.
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid?
By Chris Markoch | October 27, 2026
Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$148.05 +0.87 (+0.59%)
As of 11:42 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas